Search results
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
Zacks via Yahoo Finance· 12 hours agoBristol Myers Squibb (BMY) obtains FDA approval for the label expansion of CAR T cell therapy...
Obituary For Eminem’s Alter Ego Slim Shady Published In Detroit Newspaper
HuffPost· 2 days agoThe promotional stunt certainly teases a return to horrorcore for Eminem, whose 2009 effort “Relapse...
Kristen Bell Shares Parenting Rule She And Dax Shepard Have Related To Fights
Cinema Blend· 8 hours agoBecause while it's a dream that offers exciting opportunities, it can also make one's personal life...
FDA Approves Expanded Use Of Bristol Myers Squibb's Breyanzi Cancer Cell Therapy For Previously...
Benzinga· 9 hours agoThis indication is approved under accelerated approval based on response rate and duration of...
Steven Tyler Joins the Black Crowes Onstage in London Months After Fracturing Larynx
People via Yahoo News· 6 hours agoIn April, Aerosmith announced a new set of dates that will resume later this year and run until...
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Zacks via Yahoo Finance· 8 hours agoThe regulatory body approved Breyanzi for the treatment of adult patients with relapsed or...
FDA approves Bristol Myers Squibb’s Breyanzi for follicular lymphoma
Pharmaceutical Technology via Yahoo Finance· 17 hours agoThe US Food and Drug Administration (FDA) has granted accelerated approval for Bristol Myers...
Q1 2024 Bio Path Holdings Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 21 hours agoIt is an open-label, two-stage, multi-center study of prexigebersen in combination with decitabine and venetoclax in two cohorts of patients with previously untreated AML and refractory < ...
Bristol Myers Gets FDA OK of Breyanzi in Follicular Lymphoma
Morningstar· 14 hours agoBristol Myers Squibb has won U.S. Food and Drug Administration expanded approval of its CAR-T cell therapy Breyanzi for adults with relapsed or refractory follicular lymphoma ...
Precigen Reports First Quarter 2024 Financial Results and Business Updates
WRBL Columbus· 2 days ago– Pivotal Phase 2 study data of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis to be presented at the 2024 ASCO Annual Meeting as a late-breaking oral presentation ...
